Benjamin P. Levy, MD, talks about the role chemotherapy currently plays in an arena where the cancer care team is emphasizing genomic profiling and targeted therapies to treat patients with lung cancer.
MET alterations leading to exon 14 skipping occur in approximately 4% of lung carcinomas, resulting in MET activation and sensitivity to MET inhibitors in vitro.1 Crizotinib, initially developed as a MET inhibitor, is currently approved for the treatment of ALK-positive [ Read More ]
Metastatic non–small-cell lung cancer (NSCLC) is a recognized risk factor for venous thromboembolism (VTE). Some systemic treatments may increase this risk further. Young and colleagues presented data on the risk of VTE and its prognostic significance in patients treated with [ Read More ]